(TELA) Tela Bio - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8723811084
TELA: Tissue Matrix, Hernia Repair, Abdominal Reconstruction, Robotic Surgery
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions designed to preserve and restore patient anatomy. The company offers a range of OviTex Reinforced Tissue Matrix products, including hernia repair and abdominal wall reconstruction solutions, as well as OviTex PRS for plastic and reconstructive surgery. Additionally, OviTex is available for laparoscopic and robotic-assisted procedures, utilizing sterile reinforced tissue matrices derived from ovine rumen with polypropylene fibers. The company distributes its products primarily through a direct sales force in the United States. Founded in 2012, TELA Bio is headquartered in Malvern, Pennsylvania.
The companys product portfolio addresses unmet clinical needs in hernia repair and reconstructive surgery, focusing on minimizing complications and improving surgical outcomes. Its OviTex line combines natural and synthetic materials to provide strength and facilitate tissue regeneration, making it suitable for a variety of surgical applications. TELA Bios direct sales model allows for targeted outreach to surgeons and healthcare providers, ensuring precise alignment with clinical demands.
Based on the provided data, here is a 3-month forecast:
Technical indicators suggest TELA shares may face near-term headwinds, as the stock price (2.34) is below its 20-day (2.63) and 50-day (2.72) moving averages, signaling potential weakness. The 200-day moving average (3.46) further indicates a downtrend. Average daily volume (143,688) and ATR (0.17) suggest manageable volatility. On the fundamental side, TELAs market cap (96.50M) and P/S ratio (1.41) align with its current growth stage, while the high P/B ratio (22.99) and negative P/E suggest elevated valuations relative to book value. The exceptionally high RoE (662.04) highlights strong profitability per equity dollar, though the lack of forward P/E indicates uncertainty about future earnings. Overall, TELA may experience short-term price pressure but could stabilize as clinical adoption of its products progresses.
Additional Sources for TELA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TELA Stock Overview
Market Cap in USD | 96m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 2019-11-08 |
TELA Stock Ratings
Growth 5y | -86.5% |
Fundamental | 10.6% |
Dividend | 0.0% |
Rel. Strength Industry | -56.9 |
Analysts | 4.5/5 |
Fair Price Momentum | 1.61 USD |
Fair Price DCF | - |
TELA Dividends
No Dividends PaidTELA Growth Ratios
Growth Correlation 3m | -82.9% |
Growth Correlation 12m | -81.3% |
Growth Correlation 5y | -86.6% |
CAGR 5y | -23.75% |
CAGR/Max DD 5y | -0.26 |
Sharpe Ratio 12m | -2.50 |
Alpha | -62.90 |
Beta | 0.33 |
Volatility | 47.24% |
Current Volume | 119.9k |
Average Volume 20d | 156.2k |
As of March 16, 2025, the stock is trading at USD 2.35 with a total of 119,874 shares traded.
Over the past week, the price has changed by -2.89%, over one month by -9.96%, over three months by -15.77% and over the past year by -56.56%.
Neither. Based on ValueRay Fundamental Analyses, Tela Bio is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.61 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TELA as of March 2025 is 1.61. This means that TELA is currently overvalued and has a potential downside of -31.49%.
Tela Bio has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy TELA.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, TELA Tela Bio will be worth about 1.7 in March 2026. The stock is currently trading at 2.35. This means that the stock has a potential downside of -25.96%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9.5 | 304.3% |
Analysts Target Price | 9.5 | 304.3% |
ValueRay Target Price | 1.7 | -26% |